Fenofibrate Therapy in Carnitine Palmitoyl Transferase Type 2 Deficiency
Joint Authors
Hamilton-Craig, I.
Jayasinghe, R.
Johnson, L.
Yudi, M.
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-12-03
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Bezafibrate therapy has been shown to improve beta-oxidation of fatty acids and to reduce episodes of rhabdomyolysis in patients with carnitine palmitoyltransferase type-2 (CPT2) deficiency.
We report the efficacy of fenofibrate in a patient with CPT2 deficiency, in whom beta-oxidation was improved but an episode of rhabdomyolysis nevertheless occurred.
This suggests additional methods to avoid rhabdomyolysis in patients with CPT2 deficiency should accompany fibrate therapy, including avoidance of muscular overexertion, dehydration, and heat exposure.
American Psychological Association (APA)
Hamilton-Craig, I.& Yudi, M.& Johnson, L.& Jayasinghe, R.. 2012. Fenofibrate Therapy in Carnitine Palmitoyl Transferase Type 2 Deficiency. Case Reports in Medicine،Vol. 2012, no. 2012, pp.1-4.
https://search.emarefa.net/detail/BIM-450898
Modern Language Association (MLA)
Hamilton-Craig, I.…[et al.]. Fenofibrate Therapy in Carnitine Palmitoyl Transferase Type 2 Deficiency. Case Reports in Medicine No. 2012 (2012), pp.1-4.
https://search.emarefa.net/detail/BIM-450898
American Medical Association (AMA)
Hamilton-Craig, I.& Yudi, M.& Johnson, L.& Jayasinghe, R.. Fenofibrate Therapy in Carnitine Palmitoyl Transferase Type 2 Deficiency. Case Reports in Medicine. 2012. Vol. 2012, no. 2012, pp.1-4.
https://search.emarefa.net/detail/BIM-450898
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-450898